Prostate cancer diagnosis: Get the target!
Poster Session 46

Sunday 18 March
14:00 - 15:30

Location: Red Area, Room 2 (Level 0)
Chairs: C.F. Kweldam, Rotterdam (NL)
R. Rabenalt, Düsseldorf (DE)
K. Touijer, New York (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

617 Automated diagnosis of prostate cancer location by artificial intelligence in multiparametric MRI

By: Oishi Y.1, Kitta T.1, Shinohara N.1, Nosato H.2, Sakanashi H.2, Murakawa M.2
1Graduate School of Medicine, Hokkaido University, Dept. of Renal and Genitourinary Surgery, Sapporo Hokkaido, Japan, 2National Institute of Advanced Industrial Science and Technology, AI Research Center, Tsukuba Ibaraki, Japan

618 Defining the target prior to prostate fusion biopsy: The effect of MRI reporting on cancer detection

By: Westhoff N.1, Siegel F.1, Peter C.1, Von Hardenberg J.1, Michel M.S.1, Budjan J.2, Ritter M.1
1University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, 2University Medical Center Mannheim, Institute of Clinical Radiology and Nuclear Medicine, Mannheim, Germany

619 Simple biparametric MRI in detection and ruling out significant prostate cancer in biopsy-naïve men (BIDOC study)

By: Boesen L.P.1, Nørgaard N.1, Løgager V.2, Balslev I.3, Thestrup K-C.2, Winther M2, Bisbjerg R.1, Jakobsen H.1, Thomsen H.2
1Herlev Gentofte University Hospital, Dept. of Urology, Herlev, Denmark, 2Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark, 3Herlev Gentofte University Hospital, Dept. of Pathology, Herlev, Denmark

620 Biparametric MRI: Could it reduce the cost of MRI while maintaining diagnostic accuracy for prostate cancer?

By: Grummet J.1, Pepdjonovic L.1, Huang S.1, Dat A.1, Miller R.1, Begashaw K.1, Kalapara A.1, Mann S.1, Ryan A.2, O’Sullivan R.3, Moon D.1, Landau A.1, Snow R.1, Hanegbi U.1, Frydenberg M.1
1Australian Urology Associates, Dept. of Urology, Melbourne, Australia, 2Tissupath, Dept.
Inter-reader agreement of Prostate Imaging Reporting and Data System version 2 in detecting prostate cancer on 3 Tesla multiparametric MRI: A prospective study on patients referred to radical prostatectomy

By: Giannarini G. 1, Girometti R. 2, Sioletic S. 3, Rossanese M. 4, Palumbo V. 5, Calandriello M. 1, Crestani A. 1, Zuiani C. 2, Ficarra V. 1

1 Academic Medical Centre “Santa Maria della Misericordia”, Dept. of Urology, Udine, Italy, 2 University of Udine, Dept. of Medicine, Institute of Radiology, Udine, Italy, 3 Academic Medical Centre “Santa Maria della Misericordia”, Dept. of Pathology, Udine, Italy, 4 University of Catania, Dept. of Urology, Catania, Italy, 5 University of Messina, Dept. of Human and Pediatric Pathology “Gaetano Barresi”, Urologic Section, Messina, Italy

Multiparametric magnetic resonance of the prostate second opinion may reduce the number of unnecessary biopsies: A single center experience

By: Luzzago S. 1, Catellani M. 1, Mistretta F.A. 1, Conti A. 1, Serino A. 1, Bianco R. 1, Russo A. 1, Di Trapani E. 1, Ferro M. 1, Alessi S. 2, Petralia G. 2, Musi G. 1, Matei D.V. 1, De Cobelli O. 1

1 IEO European Institute of Oncology, Dept. of Urology, Milan, Italy, 2 IEO European Institute of Oncology, Dept. of Radiology, Milan, Italy

Assessing the impact of radiologist expertise on the misdiagnosis of clinically significant prostate cancer among men receiving multi-parametric MRI

By: Dell'Oglio P. 1, Stabile A. 1, Bravi C.A. 1, Mazzone E. 1, Fossati N. 1, Gandaglia G. 1, Esposito A. 2, Brembilla G. 2, Brunetti L. 2, Grande P. 3, Shariat S. 4, De La Taille A. 5, Karakiewicz P. 6, De Cobelli F. 2, Montorsi F. 1, Briganti A. 1

1 Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2 Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy, 3 Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, University Paris Sorbonne, Dept. of Urology, Paris, France, 4 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 5 CHU Mondor, Assistance Publique des Hopitaux de Paris - University Paris-Est France, Dept. of Urology, Creteil, France, 6 University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

The FUTURE trial: A RCT on MRI targeted prostate biopsy. Comparison of targeted and systematic biopsy outcomes

By: Exterkate L. 1, Wegelin O. 2, Van Melick H. 2, Barentsz J. 3, Van Der Leest M. 3, Kummer A. 4, Vreuls W. 5, De Bruin P. 4, Bosch R. 6, Somford D. 1

1 Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, Netherlands, The, 2 St. Antonius Hospital, Dept. of Urology, Nieuwegein/Utrecht, Netherlands, The, 3 Radboud University Medical Centre, Dept. of Radiology, Nijmegen, Netherlands, The, 4 St. Antonius Hospital, Dept. of Pathology, Nieuwegein/Utrecht, Netherlands, The, 5 Canisius Wilhelmina
625

**The urologist's learning curve for MRI/TRUS fusion guided prostate biopsy**

By: De Castro Abreu A.L.¹, Oishi M.¹, Lin-Brande M.¹, Cacciamani G.E.¹, Ashrafi A.N.¹, Shin T.¹, Freitas D.¹, Fay C.¹, Ohe C.¹, Winter M.¹, Margaryan T.¹, Aron M.², Chen F.³, Ukimura O.¹, Palmer S.³, Gill I.S.¹

¹USC/Norris Cancer Center, Dept. of Urology, Los Angeles, United States of America, ²Keck Medical Center of USC, Dept. of Pathology, Los Angeles, United States of America, ³Keck Medical Center of USC, Dept. of Radiology, Los Angeles, United States of America

626

**Number and spatial distribution of cores in multiparametric-magnetic resonance/ultrasound fusion prostate biopsy: Is there a role in the index tumor detection and characterization?**

By: Porpiglia F.¹, De Luca S.¹, Manfredi M.¹, Mele F.¹, Bertolo R.¹, Garrou D.¹, Ampatore D.¹, Checcucci E.¹, Giordano A.¹, Ragni F.¹, Bombaci S.¹, Gned D.², De Pascale A.², Fiori A.¹

¹San Luigi Gonzaga Hospital, Dept. of Urology, Orbassano, Italy, ²San Luigi Gonzaga Hospital, Dept. of Radiology, Orbassano, Italy

627

**Initial results comparing 29 MHz micro-ultrasound with multi-parametric MRI for targeted prostate biopsy: Relative sensitivity to clinically significant prostate cancer**

By: Astobieta Odriozola A.¹, Sanchez A.¹, De La Cruz I.¹, Pereira J.G.¹, Gamarra M.¹, Urdaneta F.¹, Mora J.¹, Ibarluzea G.¹

Clinica IMQ Zorrotzaurre, Dept. of Urology, Bilbao, Spain

628

**Prostate cancer diagnosis by three-dimensional contrast-ultrasound dispersion imaging**

By: Schalk S.¹, Huang J.², Li J.², Wijkstra H.³, Huang P.², Mischi M.¹

¹Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, Netherlands, The, ²Second Affiliated Hospital of Zhejiang University, Dept. of Ultrasound, Hangzhou, China, ³Academic Medical Center University of Amsterdam, Dept. of Urology, Amsterdam, Netherlands, The

629

**Which patients should consider and which patients could safely avoid prostate biopsy in the setting of negative mpMRI?**

By: Oishi M.¹, Ashrafi A.N.¹, Cacciamani G.E.¹, Shin T.¹, Ohe C.¹, Ghodoussipour S.¹, Lin-Brande M.¹, Winter M.¹, Medina L.¹, Margaryan T.¹, Palmer S.², Aron M.³, Ukimura O.⁴, Gill I.¹, De Castro Abreu A.L.¹

¹University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ²University of Southern California, Dept. of Radiology, Los Angeles, United States of America, ³University of Southern California, Dept. of Pathology, Los Angeles, United
<table>
<thead>
<tr>
<th>Index</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>630</td>
<td>Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience</td>
<td>States of America, 4Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan</td>
</tr>
<tr>
<td>631</td>
<td>Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer</td>
<td>Voss J.1, Pal R.1, Hannah M.1, Ahmed S.1, Jaulim A.2, Walton T.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Nottingham University Hospitals NHS Trust, Dept. of Urology, Nottingham, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom</td>
</tr>
</tbody>
</table>